In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.
Taro Pharmaceutical Industries’ US subsidiary has become the fifth pharmaceutical company to admit that it conspired to fix the prices of generic medicines, agreeing to pay a $205.7m criminal penalty as part of a three-year deferred prosecution agreement with the US Department of Justice.
The Sun Pharma affiliate – which admitted that its sales affected by the charged conspiracies “exceeded $500m” – is also...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
